Summary

The global renal anemia treatment market is estimated to grow from US$8.0 billion in 2024 to US$12.3 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.3% during the forecast period. This growth is underpinned by several key factors and trends shaping the market:

Key Market Highlights

• Current Market Value (2024): US$8.0 billion
• Projected Market Value (2031): US$12.3 billion
• CAGR (2024-2031): 6.3%

Market Drivers

1. Increasing Prevalence of Chronic Kidney Disease (CKD): The rising global prevalence of CKD is a major driver of the renal anemia treatment market. As CKD becomes more common, the incidence of anemia as a complication is also increasing, fueling demand for effective treatment options.
2. Advancements in Treatment Options: Ongoing advancements in treatment technologies are contributing to market growth. Innovations in drug development and therapeutic approaches are enhancing the management of renal anemia, providing more effective solutions for patients.
3. Growing Awareness: There is an increasing awareness of anemia as a complication of CKD, which is driving demand for renal anemia treatments. Enhanced awareness among healthcare providers and patients is contributing to greater adoption of available treatment options.
4. Aging Global Population: The global aging population is expected to drive the prevalence of renal anemia, as older individuals are more likely to suffer from CKD and its complications. This demographic trend is anticipated to further boost the demand for renal anemia treatments.
5. Research and Development Investments: Significant investments in research and development are expected to drive innovation in the renal anemia treatment market. New product developments and improvements in existing treatments will contribute to market expansion.

Regional Insights

Dominance of the US Market:

Favorable reimbursement policies and early adoption of advanced treatments in the US are expected to drive the market in North America. The US market benefits from strong healthcare infrastructure and high levels of investment in medical research.
Increasing Prevalence in the UK:

The growing prevalence of iron deficiency anemia in the UK, coupled with innovative technologies and evolving lifestyle patterns, is projected to drive market growth in the region. Rising per capita income and the entry of established companies are also contributing to increased demand for renal anemia treatments.

Key Trends

• Innovative Technologies: Technological advancements in treatment options are enhancing the efficacy of renal anemia management, contributing to market growth.
• Rising Lifestyle-Related Anemia Cases: Evolving lifestyle patterns are impacting anemia rates, leading to increased demand for effective treatment solutions.
• New Product Launches: The surge in new product launches is expected to fuel market growth by providing patients and healthcare providers with a wider range of treatment options.

Conclusion

The renal anemia treatment market is on a growth trajectory, driven by the increasing prevalence of CKD, advancements in treatment options, and a rising awareness of anemia as a CKD complication. With ongoing investments in research and development, and an aging global population, the market is poised for significant expansion in the coming years.

Key Companies Profiled:

• Johnson & Johnson
• Roche Holding AG
• Fresenius Medical Care AG & Co. KGaA
• Pharmacosmos A/S
• Vifor Pharma Group
• Kyowa Kirin Co., Ltd.
• Rockwell Medical, Inc.
• Akebia Therapeutics, Inc.
• AMAG Pharmaceuticals, Inc.

Renal Anemia Treatment Industry Segmentation

By Treatment

• Medications
• Dietary Supplements

By Disease

• Normocytic anemia
• Microcytic anemia
• Macrocytic anemia

By Distribution Channel

• Institutional Pharmacies
• Retail Pharmacies
• Mail Order Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Middle East
• Oceania
• Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Renal Anemia Treatment Market Snapshot, 2024-2031
1.2. Market Opportunity Assessment, 2024-2031, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Epidemiology - Disease Prevalence and Incidence
3.2. Technology Assessment
3.3. Regulatory Landscape
3.4. Value Chain Analysis
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Porter's Five Force Analysis
4. Global Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023-2031
4.3. Global Renal Anemia Treatment Market Outlook: Treatment
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Treatment, 2019-2023
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
4.3.3.1. Medications
4.3.3.2. Dietary Supplements
4.4. Market Attractiveness Analysis: Treatment
4.5. Global Renal Anemia Treatment Market Outlook: Disease
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Disease, 2019-2023
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
4.5.3.1. Normocytic anemia
4.5.3.2. Microcytic anemia
4.5.3.3. Macrocytic anemia
4.6. Market Attractiveness Analysis: Disease
4.7. Global Renal Anemia Treatment Market Outlook: Distribution Channel
4.7.1. Introduction / Key Findings
4.7.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
4.7.3.1. Normocytic anemia
4.7.3.2. Microcytic anemia
4.7.3.3. Macrocytic anemia
4.8. Market Attractiveness Analysis: Distribution Channel
5. Global Renal Anemia Treatment Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
6.2.1. By Country
6.2.2. By Treatment
6.2.3. By Disease
6.2.4. By Distribution Channel
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
6.4.1. Medications
6.4.2. Dietary Supplements
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
6.5.1. Normocytic anemia
6.5.2. Microcytic anemia
6.5.3. Macrocytic anemia
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
6.6.1. Institutional Pharmacies
6.6.2. Retail Pharmacies
6.6.3. Mail Order Pharmacies
6.7. Market Attractiveness Analysis
7. Europe Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
7.2.1. By Country
7.2.2. By Treatment
7.2.3. By Disease
7.2.4. By Distribution Channel
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
7.4.1. Medications
7.4.2. Dietary Supplements
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
7.5.1. Normocytic anemia
7.5.2. Microcytic anemia
7.5.3. Macrocytic anemia
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
7.6.1. Institutional Pharmacies
7.6.2. Retail Pharmacies
7.6.3. Mail Order Pharmacies
7.7. Market Attractiveness Analysis
8. East Asia Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
8.2.1. By Country
8.2.2. By Treatment
8.2.3. By Disease
8.2.4. By Distribution Channel
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
8.4.1. Medications
8.4.2. Dietary Supplements
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
8.5.1. Normocytic anemia
8.5.2. Microcytic anemia
8.5.3. Macrocytic anemia
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
8.6.1. Institutional Pharmacies
8.6.2. Retail Pharmacies
8.6.3. Mail Order Pharmacies
8.7. Market Attractiveness Analysis
9. South Asia & Oceania Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
9.2.1. By Country
9.2.2. By Treatment
9.2.3. By Disease
9.2.4. By Distribution Channel
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
9.4.1. Medications
9.4.2. Dietary Supplements
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
9.5.1. Normocytic anemia
9.5.2. Microcytic anemia
9.5.3. Macrocytic anemia
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
9.6.1. Institutional Pharmacies
9.6.2. Retail Pharmacies
9.6.3. Mail Order Pharmacies
9.7. Market Attractiveness Analysis
10. Latin America Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
10.2.1. By Country
10.2.2. By Treatment
10.2.3. By Disease
10.2.4. By Distribution Channel
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
10.4.1. Medications
10.4.2. Dietary Supplements
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
10.5.1. Normocytic anemia
10.5.2. Microcytic anemia
10.5.3. Macrocytic anemia
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
10.6.1. Institutional Pharmacies
10.6.2. Retail Pharmacies
10.6.3. Mail Order Pharmacies
10.7. Market Attractiveness Analysis
11. Middle East & Africa Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
11.2.1. By Country
11.2.2. By Treatment
11.2.3. By Disease
11.2.4. By Distribution Channel
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
11.4.1. Medications
11.4.2. Dietary Supplements
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
11.5.1. Normocytic anemia
11.5.2. Microcytic anemia
11.5.3. Macrocytic anemia
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
11.6.1. Institutional Pharmacies
11.6.2. Retail Pharmacies
11.6.3. Mail Order Pharmacies
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2023
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Amgen Inc.
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Johnson & Johnson
12.3.3. Roche Holding AG
12.3.4. Fresenius Medical Care AG & Co. KGaA
12.3.5. Pharmacosmos A/S
12.3.6. Vifor Pharma Group
12.3.7. Kyowa Kirin Co., Ltd.
12.3.8. Rockwell Medical, Inc.
12.3.9. Akebia Therapeutics, Inc.
12.3.10. AMAG Pharmaceuticals, Inc.
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations